OMER : Analysis & Opinions

  1. Omeros Renal Drug Shows Promise in Phase II (OMER)

    October 17, 2016
    Omeros Corporation said its OMS721 drug produced positive results for treating kidney diseases in a Phase II trial.
  2. Every Biotech Catalyst Wedbush Is Watching In 2016

    January 2, 2016
    In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals ...
  3. Omeros Corporation's Stock Surges

    August 20, 2015
    Omeros Corporation (OMER), a Seattle-based biopharmaceutical company, reported an additional positive data from a Phase 2 ...
  4. Four Key Pharmaceuticals ETFs To Consider

    March 25, 2015
    ETF funds are now very liquid investments and are suitable to investors who seek to match the price performance of the indexes ...
Trading Center